Sensitizing solid tumors to CAR-mediated cytotoxicity using synthetic antigens
Gamboa, L.; Zamat, A. H.; Vanover, D.; Thiveaud, C. A.; Peck, H. E.; Phuengkham, H.; Sivakumar, A.; Harris, A. M.; Dahotre, S. N.; Su, F.-Y.; Santangelo, P. J.; Kwong, G. A.
Show abstract
CAR T cell immunotherapy relies on CAR targeting of tumor-associated antigens, yet heterogenous antigen expression, interpatient variation, and off-tumor expression by healthy cells remain barriers. Here, we develop synthetic antigens to sensitize solid tumors for recognition and elimination by CAR T cells. Unlike tumor-associated antigens, we design synthetic antigens that are orthogonal to endogenous proteins to eliminate off-tumor targeting and that have a small genetic footprint to facilitate efficient tumor delivery to tumors by viral vectors. Using the RSV-F camelid single-domain antibody (VHH) as a synthetic antigen, we show that adoptive transfer of VHH CAR T cells to mice bearing VHH expressing tumors reduced tumor burden in multiple syngeneic mouse models of cancer, improved survival, induced epitope spread, and protected against tumor rechallenge. Our work supports in situ delivery of synthetic antigens to treat antigen low or negative tumors with CAR T cells.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A new universal chimeric-antigen receptor (CAR)- fragment antibody binder (FAB) split system for cancer immunotherapy 95%
- TET2 regulates early and late transitions in exhausted CD8+ T-cell differentiation and limits CAR T-cell function 95%
- In vivo mRNA delivery to virus-specific T cells by light-induced ligand exchange of MHC class I antigen-presenting nanoparticles 95%
Similar papers in this journal
- Effective Combination Immunotherapy using Oncolytic Viruses to Deliver CAR Targets to Solid Tumors 95%
- Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers 94%
- Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade 94%
Similar papers in this journal
- Rapid establishment of a tumor-retained state curtails the contribution of conventional NK cells to anti-tumor immunity in solid cancers 96%
- Lymphatic-Preserving Treatment Sequencing with Immune Checkpoint Inhibition Unleashes cDC1-Dependent Antitumor Immunity in HNSCC 95%
- Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors 95%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.